以COVID-19治疗为重点的伊维菌素药物相互作用

P. Udaykumar, Bhavya Shetty, Anurag Kundapur
{"title":"以COVID-19治疗为重点的伊维菌素药物相互作用","authors":"P. Udaykumar, Bhavya Shetty, Anurag Kundapur","doi":"10.4103/mjmsr.mjmsr_19_21","DOIUrl":null,"url":null,"abstract":"Treatment of COVID-19 largely depends on previously used drugs as there is no cure available coupled with shortage of effective vaccine with doubts about its long-term protection due to rapid viral mutations. Ivermectin, a derivative of avermectin, introduced as an antiparasitic agent, is effective against onchocerciasis, strongyloidiasis, ascariasis, filariasis, scabies, malaria, and has a good safety profile. Ivermectin is being promoted for the treatment of COVID-19, although US Food and Drug Administration has not approved its use for any viral infection. With increasing evidences indicating the efficacy of ivermectin in COVID-19 and post-COVID-19 syndrome, there is a need to focus on the drug interactions with the dose used for indication as most of the documented interactions are with the dose used for parasitic infections. As majority of the COVID-19 patients have comorbidities and on multiple drugs, it is necessary to understand the drug interactions of ivermectin.","PeriodicalId":19108,"journal":{"name":"Muller Journal of Medical Sciences and Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug interactions of ivermectin with a focus on COVID-19 treatment\",\"authors\":\"P. Udaykumar, Bhavya Shetty, Anurag Kundapur\",\"doi\":\"10.4103/mjmsr.mjmsr_19_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Treatment of COVID-19 largely depends on previously used drugs as there is no cure available coupled with shortage of effective vaccine with doubts about its long-term protection due to rapid viral mutations. Ivermectin, a derivative of avermectin, introduced as an antiparasitic agent, is effective against onchocerciasis, strongyloidiasis, ascariasis, filariasis, scabies, malaria, and has a good safety profile. Ivermectin is being promoted for the treatment of COVID-19, although US Food and Drug Administration has not approved its use for any viral infection. With increasing evidences indicating the efficacy of ivermectin in COVID-19 and post-COVID-19 syndrome, there is a need to focus on the drug interactions with the dose used for indication as most of the documented interactions are with the dose used for parasitic infections. As majority of the COVID-19 patients have comorbidities and on multiple drugs, it is necessary to understand the drug interactions of ivermectin.\",\"PeriodicalId\":19108,\"journal\":{\"name\":\"Muller Journal of Medical Sciences and Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Muller Journal of Medical Sciences and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/mjmsr.mjmsr_19_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Muller Journal of Medical Sciences and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/mjmsr.mjmsr_19_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

COVID-19的治疗在很大程度上依赖于以前使用的药物,因为没有治愈方法,再加上缺乏有效的疫苗,而且由于病毒快速突变,人们对其长期保护作用表示怀疑。伊维菌素是阿维菌素的衍生物,作为一种抗寄生虫剂引入,对盘尾丝虫病、圆线虫病、蛔虫病、丝虫病、疥疮、疟疾有效,并且具有良好的安全性。尽管美国食品和药物管理局尚未批准将伊维菌素用于任何病毒感染,但伊维菌素正在被推广用于治疗COVID-19。随着越来越多的证据表明伊维菌素对COVID-19和COVID-19后综合征的疗效,有必要关注用于适应症的剂量与药物的相互作用,因为大多数记录的相互作用与用于寄生虫感染的剂量有关。由于大多数新冠肺炎患者存在合并症,且使用多种药物,因此有必要了解伊维菌素的药物相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Drug interactions of ivermectin with a focus on COVID-19 treatment
Treatment of COVID-19 largely depends on previously used drugs as there is no cure available coupled with shortage of effective vaccine with doubts about its long-term protection due to rapid viral mutations. Ivermectin, a derivative of avermectin, introduced as an antiparasitic agent, is effective against onchocerciasis, strongyloidiasis, ascariasis, filariasis, scabies, malaria, and has a good safety profile. Ivermectin is being promoted for the treatment of COVID-19, although US Food and Drug Administration has not approved its use for any viral infection. With increasing evidences indicating the efficacy of ivermectin in COVID-19 and post-COVID-19 syndrome, there is a need to focus on the drug interactions with the dose used for indication as most of the documented interactions are with the dose used for parasitic infections. As majority of the COVID-19 patients have comorbidities and on multiple drugs, it is necessary to understand the drug interactions of ivermectin.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
12
审稿时长
26 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信